ABILIFY MAINTENA 400 mg, powder and solvent for injectable suspension with extended release in a pre-filled syringe bottle, 2 ml + 3 needles
Active ingredients: Aripiprazole
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 ml + 3 needlesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ABILIFY MAINTENA 400 mg, poudre et solvant pour suspension injectable à libération prolongée en seringue préremplie
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre de 400 mg - 1 flacon(s) en verre de 2 ml + 1 seringue préremplie + 3 aiguilles (25, 38 et 50 mm)
- Marketing authorisation holder
- OTSUKA PHARMACEUTICAL NETHERLANDS (PAYS BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Jan 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66706942CIP73001897CIP133400930018972Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ARIPIPRAZOLEpoudre | 400 mg · une seringue préremplie | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.